ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Cardiovascular Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

13,585Medicare Part D Prescriptions Filled, Including Refills

Rank: 19 out of 273

$723K Total Retail Price of All Prescriptions

Rank: 27 out of 273

987 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
24% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Louisiana
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

6% of this provider’s 987 patients filled at least one prescription for a schedule three drug, compared to an average of 2%.

Risky Drugs to Seniors

1% of this provider’s 12,222 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$53 was the average price of a prescription from this provider, compared to $60 among peers.

Prescriptions per Patient

14 is the average number of prescriptions (including refills) per patient, compared to an average of 14.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
CLOPIDOGREL 737 670 1 9
WARFARIN SODIUM 631 602 2 7
ATENOLOL 629 577 3 17
METOPROLOL SUCCINATE 546 485 4 1
PRAVASTATIN SODIUM 502 474 5 11
PLAVIX 492 458 6 12
FUROSEMIDE 490 429 7 5
LISINOPRIL 460 395 8 4
SIMVASTATIN 458 410 9 6
AMLODIPINE BESYLATE 450 414 10 2
SPIRONOLACTONE 414 364 11 20
ATORVASTATIN CALCIUM 366 321 12 8
LEVOTHYROXINE SODIUM 306 251 13 25
BENAZEPRIL HCL 255 247 14 35
CRESTOR 242 217 15 14
BISOPROLOL FUMARATE 238 222 16 45
LOSARTAN POTASSIUM 223 209 17 19
DIGOXIN 215 201 18 15
PANTOPRAZOLE SODIUM 209 192 19 41
METOPROLOL TARTRATE 163 130 20 10
LOVASTATIN 154 139 21 44
ISOSORBIDE MONONITRATE ER 148 132 22 13
DIOVAN 147 127 23 21
ENALAPRIL MALEATE 143 132 24 31
AMIODARONE HCL 141 129 25 23
CITALOPRAM HBR 139 118 26 77
HYDROCODONE-ACETAMINOPHEN 132 104 S3 27 48
OMEPRAZOLE 115 94 28 33
CARVEDILOL 113 81 29 3
HYDRALAZINE HCL 110 109 30 36
MULTAQ 105 96 31 52
ZOLPIDEM TARTRATE 98 92 32 59
COUMADIN 89 88 33 50
PRADAXA 89 74 33 22
FENOFIBRATE 85 80 35 34
POTASSIUM CHLORIDE 82 61 36 18
CILOSTAZOL 81 81 37 56
METFORMIN HCL 72 69 38 46
ESCITALOPRAM OXALATE 72 64 38 86
ALLOPURINOL 69 69 40 79
NEXIUM 68 50 41 42
BUMETANIDE 65 65 42 54
NADOLOL 64 50 43 146
TRAMADOL HCL 64 64 43 73
LIPITOR 63 63 45 29
AMLODIPINE BESYLATE-BENAZEPRIL 63 53 45 47
HYDROCHLOROTHIAZIDE 60 57 47 16
CLONIDINE HCL 60 49 47 32
SYNTHROID 59 59 49 90
VYTORIN 59 55 49 68
TORSEMIDE 58 46 51 65
NITROSTAT 58 51 51 28
RAMIPRIL 57 46 53 24
PROPRANOLOL HCL 56 43 54 148
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 23, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.